GLA
PBYI icon

Great Lakes Advisors’s Puma Biotechnology PBYI Stock Holding History

Great Lakes Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-254,738
Closed -$9.88M – 558
2019
Q1 		$9.88M Buy
+254,738
New +$7.78M 0.22% 109

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Great Lakes Advisors's PBYI Position: Q2 2019 in Review

Great Lakes Advisors sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 254,738 shares — an estimated $9.88M sold.

Great Lakes Advisors first reported a position in PBYI in Q1 2019 and held it in 1 quarter. The position peaked at $9.88M in Q1 2019. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Great Lakes Advisors reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Great Lakes Advisors sold 254,738 Puma Biotechnology shares in Q2 2019, an estimated $9.88M.
  • Great Lakes Advisors first reported a position in Puma Biotechnology in Q1 2019 and held it in 1 quarter.
  • Great Lakes Advisors's Puma Biotechnology position peaked at $9.88M in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Great Lakes Advisors's 13F filing for Q2 2019, filed 5 Aug 2019.